litlas
Log inCreate account

Hervé Tilly

Active 1983–2025

192
Papers
40,672
Citations
105
h-index
188
i10-index

Citations

Citations per year for Hervé Tilly1983: 1 citations1984: 5 citations1985: 3 citations1986: 5 citations1987: 3 citations1988: 2 citations1990: 3 citations1991: 6 citations1992: 7 citations1993: 12 citations1994: 30 citations1995: 38 citations1996: 23 citations1997: 49 citations1998: 54 citations1999: 55 citations2000: 80 citations2001: 50 citations2002: 82 citations2003: 145 citations2004: 101 citations2005: 132 citations2006: 152 citations2007: 191 citations2008: 218 citations2009: 139 citations2010: 195 citations2011: 256 citations2012: 244 citations2013: 252 citations2014: 280 citations2015: 296 citations2016: 294 citations2017: 297 citations2018: 286 citations2019: 981 citations2020: 1,108 citations2021: 1,087 citations2022: 872 citations2023: 571 citations2024: 1,055 citations2025: 491 citations2026: 5 citations1989: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,768 citing papers, 24% of this breakdownFrance: 950 citing papers, 8.2% of this breakdownChina: 777 citing papers, 6.7% of this breakdownGermany: 754 citing papers, 6.5% of this breakdownUnited Kingdom: 744 citing papers, 6.4% of this breakdownItaly: 711 citing papers, 6.2% of this breakdownCanada: 473 citing papers, 4.1% of this breakdownSpain: 450 citing papers, 3.9% of this breakdownSwitzerland: 407 citing papers, 3.5% of this breakdownJapan: 365 citing papers, 3.2% of this breakdownNetherlands: 340 citing papers, 3% of this breakdownAustralia: 301 citing papers, 2.6% of this breakdown
0%24%Other 21.7%

Institutions

Fields

  • Medicine81.5%
  • Biochemistry, Genetics and Molecular Biology13.3%
  • Immunology and Microbiology3.9%
  • Computer Science0.3%
  • Materials Science0.2%
  • Mathematics0.1%
  • Other0.7%

Topics

  • Lymphoma Diagnosis and Treatment20.3%
  • CAR-T cell therapy research6.4%
  • Chronic Lymphocytic Leukemia Research5.8%
  • CNS Lymphoma Diagnosis and Treatment5.5%
  • Viral-associated cancers and disorders4.9%
  • Cutaneous lymphoproliferative disorders research2.9%
  • Other54.2%

Coauthors

All papers

Open in search
  1. Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma

    Authors: Hervé Tilly, Franck Morschhauser, Laurie H. Sehn, Jonathan W. Friedberg, Marek Trněný, Jeff P. Sharman, Charles Herbaux, John M. Burke, Matthew Matasar, Shinya Rai, Koji Izutsu, Neha Mehta-Shah, Lucie Oberic, Adrien Chauchet, Wojciech Jurczak, Yuqin Song, Richard Greil, Larysa Mykhalska, Juan M. Bergua-Burgués, Matthew C. Cheung, Antonio Pinto, Ho-Jin Shin, Greg Hapgood, Eduardo Munhoz, Pau Abrisqueta, Jyh-Pyng Gau, Jamie Hirata, Yanwen Jiang, Mark Yan, Calvin Lee, Christopher R. Flowers, Gilles Salles - New England Journal of Medicine 2021 cited by 843

  2. CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma

    Authors: Bertrand Coiffier, Éric Lepage, Josette Brière, Raoul Herbrecht, Hervé Tilly, Réda Bouabdallah, Pierre Morel, Éric Van Den Neste, Gilles Salles, Philippe Gaulard, Félix Reyes, P Lederlin, Christian Gisselbrecht - New England Journal of Medicine 2002 cited by 5,562

  3. Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial

    Authors: Franck Morschhauser, Hervé Tilly, Aristeidis Chaidos, Pam McKay, Tycel Phillips, Sarit Assouline, Connie Lee Batlevi, Phillip L. Campbell, Vincent Ribrag, Gandhi Damaj, Michael Dickinson, Wojciech Jurczak, Maciej Kazmierczak, Stephen Opat, John Radford, Anna Schmitt, Jay Yang, Jennifer Whalen, Shefali Agarwal, Deyaa Adib, Gilles Salles - The Lancet Oncology 2020 cited by 587

  4. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte

    Authors: Bertrand Coiffier, Catherine Thiéblemont, Éric Van Den Neste, G. Lepeu, Isabelle Plantier, Sylvie Castaigné, Sophie Lefort, Gérald Marit, Margaret Macro, Catherine Sebban, Karim Belhadj, Dominique Bordessoule, Christophe Fermé, Hervé Tilly - Blood 2010 cited by 1,558

  5. International prognostic indices in diffuse large B-cell lymphoma: a comparison of IPI, R-IPI, and NCCN-IPI

    Authors: Amy S. Ruppert, Jesse G. Dixon, Gilles Salles, Anna Wall, David Cunningham, Viola Poeschel, Corinne Haïoun, Hervé Tilly, Hervé Ghesquières, Marita Ziepert, Jocelyne Flament, Christopher R. Flowers, Qian Shi, Norbert Schmitz - Blood 2020 cited by 378

  6. Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    Authors: Hervé Tilly, María Gomes da Silva, Umberto Vitolo, Andrew Jack, Michel Meignan, Armando López‐Guillermo, Jan Walewski, M. André, Peter Johnson, Michael Pfreundschuh, Marco Ladetto - Annals of Oncology 2015 cited by 925

  7. Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study

    Authors: Kim Linton, Umberto Vitolo, Wojciech Jurczak, Pieternella J. Lugtenburg, Emmanuel Gyan, Anna Sureda, Jacob Haaber Christensen, Brian Hess, Hervé Tilly, Raúl Córdoba, David Lewis, Craig Okada, Martin Hutchings, Michael Roost Clausen, Juan‐Manuel Sancho, Tara Cochrane, Sirpa Leppä, Martine E.D. Chamuleau, Diana Gernhardt, Işıl Altıntaş, Yan Liu, Tahamtan Ahmadi, Minh H. Dinh, Daniela Hoehn, Elena Favaro, Brian Elliott, Catherine Thiéblemont, Julie M. Vose - The Lancet Haematology 2024 cited by 139

  8. Event-Free Survival at 24 Months Is a Robust End Point for Disease-Related Outcome in Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy

    Authors: Matthew J. Maurer, Hervé Ghesquières, Jean‐Philippe Jais, Thomas E. Witzig, Corinne Haïoun, Carrie A. Thompson, Richard Delarue, Ivana N. Micallef, Frédéric Peyrade, William R. Macon, Thierry Jo Molina, Nicolas Ketterer, Sergei Syrbu, Olivier Fitoussi, Paul J. Kurtin, Cristine Allmer, Emmanuelle Nicolas‐Virelizier, Susan L. Slager, Thomas M. Habermann, Brian K. Link, Gilles Salles, Hervé Tilly, James R. Cerhan - Journal of Clinical Oncology 2014 cited by 410

  9. Safety and activity of the anti-CD79B antibody–drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study

    Authors: Maria Corinna Palanca-Wessels, Myron S. Czuczman, Gilles Salles, Sarit Assouline, Laurie H. Sehn, Ian W. Flinn, Manish R. Patel, Randeep Sangha, Anton Hagenbeek, Ranjana H. Advani, Hervé Tilly, Olivier Casasnovas, Oliver W. Press, Sreeni Yalamanchili, Robert S. Kahn, Randall Dere, Dan Lü, Surai Jones, Cheryl Jones, Yu-Waye Chu, Franck Morschhauser - The Lancet Oncology 2015 cited by 335

  10. TET2 Inactivation Results in Pleiotropic Hematopoietic Abnormalities in Mouse and Is a Recurrent Event during Human Lymphomagenesis

    Authors: Cyril Quivoron, Lucile Couronné, Véronique Della Valle, Cécile K. Lopez, Isabelle Plo, Orianne Wagner‐Ballon, Marcio Do Cruzeiro, François Delhommeau, Bertrand Arnulf, Marc‐Henri Stern, Lucy A. Godley, Paule Opolon, Hervé Tilly, Éric Solary, Yannis Duffourd, Philippe Dessen, Hélène Merle‐Béral, Florence Nguyen‐Khac, Michaëla Fontenay, William Vainchenker, Christian Bastard, Thomas Mercher, Olivier Bernard - Cancer Cell 2011 cited by 897

  11. Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS)

    Authors: Franck Morschhauser, Ian W. Flinn, Ranjana H. Advani, Laurie H. Sehn, Catherine Diefenbach, Kathryn S. Kolibaba, Oliver W. Press, Gilles Salles, Hervé Tilly, Andy I. Chen, Sarit Assouline, Bruce D. Cheson, Martin Dreyling, Anton Hagenbeek, Pier Luigi Zinzani, Surai Jones, Ji Cheng, Dan Lü, Elicia Penuel, Jamie Hirata, Michael Wenger, Yu-Waye Chu, Jeff P. Sharman - The Lancet Haematology 2019 cited by 249

  12. Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma

    Authors: Franck Morschhauser, Nathan Fowler, Pierre Feugier, Réda Bouabdallah, Hervé Tilly, M. Lia Palomba, Christophe Fruchart, Edward N. Libby, Olivier Casasnovas, Ian W. Flinn, Corinne Haïoun, Hervé Maisonneuve, Loïc Ysebaert, Nancy L. Bartlett, Kamal Bouabdallah, Pauline Brice, Vincent Ribrag, Nicolas Daguindau, Steven Le Gouill, Gian M. Pica, Alejandro Martı́n, Armando López‐Guillermo, Jean-François Larouche, Kiyoshi Ando, María Gomes da Silva, Marc André, Pierre Zachée, Laurie H. Sehn, Kensei Tobinai, Guillaume Cartron, David Liu, Jianming Wang, Luc Xerri, Gilles Salles - New England Journal of Medicine 2018 cited by 362

  13. Sustained Progression-Free Survival Benefit of Rituximab Maintenance in Patients With Follicular Lymphoma: Long-Term Results of the PRIMA Study

    Authors: Emmanuel Bachy, John F. Seymour, Pierre Feugier, Fritz Offner, Armando López‐Guillermo, David Belada, Luc Xerri, John Catalano, Pauline Brice, François Lemonnier, Alejandro Martı́n, Olivier Casasnovas, Lars Møller Pedersen, Véronique Dorvaux, David Simpson, Sirpa Leppä, Jean Gabarre, María Gomes da Silva, Sylvie Glaisner, Loïc Ysebaert, Anne Vekhoff, Tanin Intragumtornchai, Steven Le Gouill, Andrew Lister, Jane Estell, Giuseppe Milone, Anne Sonet, Jonathan Farhi, Harald Zeuner, Hervé Tilly, Gilles Salles - Journal of Clinical Oncology 2019 cited by 278

  14. ROSEWOOD: A Phase II Randomized Study of Zanubrutinib Plus Obinutuzumab Versus Obinutuzumab Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma

    Authors: Pier Luigi Zinzani, Jiřı́ Mayer, Christopher R. Flowers, Fontanet Bijou, Ana Carla Oliveira, Yuqin Song, Qingyuan Zhang, Michele Merli, Krimo Bouabdallah, Peter Ganly, Huilai Zhang, Roderick J. Johnson, Alejandro Martı́n, Mariano Provencio, Marek Trněný, Sam Yuen, Hervé Tilly, Edwin Kingsley, Gayane Tumyan, Sarit Assouline, Rebecca Auer, Elena V. Ivanova, Pil Kim, Sha Huang, Richard Delarue, Judith Trotman - Journal of Clinical Oncology 2023 cited by 98

  15. Long-Term Results of the R-CHOP Study in the Treatment of Elderly Patients With Diffuse Large B-Cell Lymphoma: A Study by the Groupe d'Etude des Lymphomes de l'Adulte

    Authors: Pierre Feugier, Ambro van Hoof, Catherine Sebban, P. Solal-Céligny, Réda Bouabdallah, Christophe Fermé, B. Christian, Éric Lepage, Hervé Tilly, Franck Morschhauser, Philippe Gaulard, Gilles Salles, André Bosly, Christian Gisselbrecht, F Reyes, Bertrand Coiffier - Journal of Clinical Oncology 2005 cited by 1,499

  16. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte.

    Authors: Pauline Brice, Y Bastion, Éric Lepage, Nicole Brousse, Corinne Haïoun, Philippe Moreau, Nicole Straetmans, Hervé Tilly, I Tabah, Philippe Solal‐Céligny - Journal of Clinical Oncology 1997 cited by 641

  17. High total metabolic tumor volume at baseline predicts survival independent of response to therapy

    Authors: Laëtitia Vercellino, Anne‐Ségolène Cottereau, Olivier Casasnovas, Hervé Tilly, Pierre Feugier, Loïc Chartier, Christophe Fruchart, Louise Roulin, Lucie Obéric, Gian Matteo Pica, Vincent Ribrag, Julie Abraham, Marc A. Simon, Hugo González, Réda Bouabdallah, Olivier Fitoussi, Catherine Sebban, Armando López‐Guillermo, Laurence Sanhès, Franck Morschhauser, Judith Trotman, Bernadette Corront, Bachra Choufi, Sylvia Snauwaert, Pascal Godmer, Josette Brière, Gilles Salles, Philippe Gaulard, Michel Meignan, Catherine Thiéblemont - Blood 2020 cited by 185

  18. Six-Year Results From RELEVANCE: Lenalidomide Plus Rituximab (R2) Versus Rituximab-Chemotherapy Followed by Rituximab Maintenance in Untreated Advanced Follicular Lymphoma

    Authors: Franck Morschhauser, Loretta J. Nastoupil, Pierre Feugier, Jean‐Marc Schiano de Colella, Hervé Tilly, Maria Lia Palomba, Emmanuel Bachy, Christophe Fruchart, Edward N. Libby, Olivier Casasnovas, Ian W. Flinn, Corinne Haïoun, Hervé Maisonneuve, Loïc Ysebaert, Nancy L. Bartlett, Kamal Bouabdallah, Pauline Brice, Vincent Ribrag, Steven Le Gouill, Nicolas Daguindau, Stéphanie Guidez, Gian Matteo Pica, Alejandro Martı́n, Armondo López-Guillermo, Jean-François Larouche, Kiyoshi Ando, María Gomes da Silva, Marc André, Wu Kalung, Laurie H. Sehn, Koji Izutsu, Guillaume Cartron, Argyrios Gkasiamis, Russell Crowe, Luc Xerri, Nathan Fowler, Gilles Salles - Journal of Clinical Oncology 2022 cited by 68

  19. A Phase 1 Study of Plamotamab, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma: Recommended Dose Safety/Efficacy Update and Escalation Exposure-Response Analysis

    Authors: Krish Patel, Peter A. Riedell, Hervé Tilly, Sairah Ahmed, Jean‐Marie Michot, Hervé Ghesquières, Jean Marc Schiano de Collela, Asher Chanan‐Khan, Kamal Bouabdallah, Benoît Tessoulin, Sunil Iyengar, Meixiao Long, Raphael Clynes, Jitendra Kanodia, Lei Bao, Ying Ding, Jianhua Jin, William B. Ainsworth, Raman Garcha, Steve Kye, Tycel Phillips - Blood 2022 cited by 38

  20. Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial

    Authors: Frédéric Peyrade, Fabrice Jardin, Catherine Thiéblemont, Antoine Thyss, Jean‐François Emile, Sylvie Castaigné, Bertrand Coiffier, Corinne Haïoun, Serge Bologna, Olivier Fitoussi, G. Lepeu, Christophe Fruchart, Dominique Bordessoule, Michel Blanc, Richard Delarue, Maud Janvier, Bruno César Corrêa Salles, Marc André, Marion Fournier, Philippe Gaulard, Hervé Tilly - The Lancet Oncology 2011 cited by 545

  21. A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts

    Authors: Sarah Huet, Bruno Tesson, Jean‐Philippe Jais, Andrew L. Feldman, Laura Magnano, Emilie Thomas, Alexandra Traverse‐Glehen, Benoît Albaud, Marjorie Carrère, Luc Xerri, Stephen M. Ansell, Lucile Baseggio, Cécile Réyès, Karin Tarte, Sandrine Boyault, Corinne Haïoun, Brian K. Link, Pierre Feugier, Armando López‐Guillermo, Hervé Tilly, Pauline Brice, Sandrine Hayette, Fabrice Jardin, Fritz Offner, Pierre Sujobert, David Gentien, Alain Viari, Elı́as Campo, James R. Cerhan, Gilles Salles - The Lancet Oncology 2018 cited by 220

  22. Targeted genotyping of circulating tumor DNA for classical Hodgkin lymphoma monitoring: a prospective study

    Authors: Vincent Camus, Mathieu Viennot, Justine Lequesne, Pierre‐Julien Viailly, Élodie Bohers, Lucile Bessi, B. Marcq, Pascaline Etancelin, Sydney Dubois, Jean‐Michel Picquenot, Elena‐Liana Veresezan, Marie Cornic, Lucie Burel, Justine Loret, Stéphanie Becker, Pierre Decazes, Pascal Lenain, Stéphane Leprêtre, Émilie Lemasle, Hélène Lanic, Anne‐Lise Ménard, Nathalie Contentin, Hervé Tilly, Aspasia Stamatoullas, Fabrice Jardin - Haematologica 2020 cited by 106

  23. Baseline Metabolic Tumor Volume Predicts Outcome in High–Tumor-Burden Follicular Lymphoma: A Pooled Analysis of Three Multicenter Studies

    Authors: Michel Meignan, Anne‐Ségolène Cottereau, Annibale Versari, Loïc Chartier, Jehan Dupuis, Sami Boussetta, Ilaria Grassi, Olivier Casasnovas, Corinne Haïoun, Hervé Tilly, Vittoria Tarantino, Julien Dubreuil, Massimo Federico, Gilles Salles, Stefano Luminari, Judith Trotman - Journal of Clinical Oncology 2016 cited by 337

  24. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial

    Authors: Gilles Salles, John F. Seymour, Fritz Offner, Armando López‐Guillermo, David Belada, Luc Xerri, Pierre Feugier, Réda Bouabdallah, John Catalano, Pauline Brice, Dolores Caballero, Corinne Haïoun, Lars Møller Pedersen, Alain Delmer, David Simpson, Sirpa Leppä, Pierre Soubeyran, Anton Hagenbeek, Olivier Casasnovas, Tanin Intragumtornchai, Christophe Fermé, María Gomes da Silva, Catherine Sebban, Andrew Lister, Jane Estell, Giuseppe Milone, Anne Sonet, Myriam Mendila, Bertrand Coiffier, Hervé Tilly - The Lancet 2010 cited by 1,066